PharmiNews

The Directory of Pharma Companies and News

Genentech

Genentech logo

Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
Category: Biotech
Category: Biotech

Genentech News

DateNews
2017-07-10Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
2017-06-25Genentech’s Emicizumab Showed Positive Results in Phase III Studies (HAVEN 1 And HAVEN 2) in Hemophilia A With Inhibitor...
2017-06-22FDA Approves Rituxan Hycela (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers
2017-06-22New Data at EAN Show Genentech’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures of Disease Progression in...
2017-06-05APHINITY Study Shows Genentech’s Perjeta-Based Regimen Reduced the Risk of Invasive Cancer Returning Compared to Hercept...
2017-06-05Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Ha...
2017-05-22FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
2017-05-10Genentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clini...
2017-05-09Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) In People With Previously Treated Advanced Blad...
2017-04-25New Data at AAN Reinforce Clinical Benefit of Genentech’s Ocrevus (Ocrelizumab) for Relapsing and Primary Progressive Mu...
2017-04-18Genentech to Present New Data at AAN Reinforcing Efficacy And Safety of Newly FDA Approved Ocrevus (Ocrelizumab) in Two ...
2017-04-17FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanc...
2017-04-17FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among...
2017-04-16Genentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with Hemophilia A
2017-04-09Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer
2017-03-29FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers
2017-03-28FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis
2017-03-23FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
2017-03-01Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer...
2017-02-17Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People with ...
2017-01-23FDA Grants Priority Review For Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application For Giant C...
2017-01-08FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bla...
2017-01-05FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
2016-12-21Positive Phase III Results of Genentech’s Investigational Medicine Ocrevus™ (Ocrelizumab) Published in New England Journ...
2016-12-21Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
2016-12-20FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
2016-12-06FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer
2016-12-04Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer without their D...
2016-11-12Phase III GiACTA Study Shows Genentech’s Actemra® is Superior to Steroids Alone in Maintaining Steroid-Free Remission fo...
2016-11-03Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual M...
2016-11-01Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARH...
2016-10-18FDA Approves Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) for People with a Specific Type of Metastatic Lu...
2016-10-14FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
2016-10-10FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application f...
2016-10-08Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy Regardless of PD-L1 ...
2016-10-04FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Va...
2016-10-03FDA Grants Breakthrough Therapy Designation for Genentech’s Alecensa® (Alectinib) for First-Line Treatment of People wit...
2016-09-13Phase III Efficacy Results of Investigational Medicine Ocrevus™ (Ocrelizumab) Reinforced by Exploratory Analyses in Two ...
2016-08-31Phase III Study Showed Genentech’s Cancer Immunotherapy TECENTRIQTM (Atezolizumab) Helped People with a Specific Type of...
2016-07-17Genentech Provides Update on Phase III Study of Gazyva® in People with Previously Untreated Diffuse Large B-Cell Lymphom...
2016-07-07FDA Approves Genentech’s Xolair® (omalizumab) for Allergic Asthma in Children
2016-06-27FDA Grants Priority Review for Genentech’s OCREVUS™ (Ocrelizumab) Biologics License Application
2016-06-05Genentech’s Cancer Immunotherapy Tecentriq™ (Atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bl...
2016-06-05Phase III Study Shows Genentech’s Actemra® (tocilizumab) Maintained Steroid-Free Remission in People with Giant Cell Art...
2016-05-26Genentech’s Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in People with Previously Untreated F...
2016-05-18FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ™ (atezolizumab) Accelerated Approval for People with a Specific Ty...
2016-05-18Phase III Study of Genentech’s Alecensa® (alectinib) Showed Superior Efficacy Versus Crizotinib in Japanese People with ...
2016-05-02Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (AS...
2016-04-12Genentech to Present New Data at AAN Showing Superior Efficacy of Investigational Medicine Ocrelizumab Versus Comparator...
2016-04-11Genentech Announces FDA Grants Venclexta™ (Venetoclax) Accelerated Approval for People with a Hard-To-Treat Type of Chro...
2016-04-10FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
2016-03-14FDA Grants Genentech’s Cancer Immunotherapy Atezolizumab Priority Review for Advanced Bladder Cancer
2016-03-01FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Pediatric Allergic Asthma
2016-02-28Genentech Provides Update on Two Identical Phase III Studies of Lebrikizumab in People with Severe Asthma
2016-02-26FDA Approves Genentech’s Gazyva (Obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma
2016-02-16FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive ...
2016-01-12FDA Grants Priority Review for Venetoclax New Drug Application
2015-12-11FDA Grants Genentech’s Alecensa® (Alectinib) Accelerated Approval for People with a Specific Type of Lung Cancer
2015-12-06Pivotal Phase II Study Showed Nearly 80 Percent of People with Hard-to-treat Type of Chronic Lymphocytic Leukemia Respon...
2015-12-05New Results from CLL11 Study Show Gazyva® Provided People with Previously Untreated Chronic Lymphocytic Leukemia a Treat...
2015-11-21Updated Data Showed That Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) Helped People With a Specif...
2015-11-10FDA Approves Genentech’s Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) in Advanced Melanoma
2015-11-05Genentech to Present New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2015 Annual ...
2015-10-08Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Prim...
2015-09-27Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Scle...
2015-09-26Genentech Presents Positive Results from Pivotal Study of Investigational Immunotherapy Atezolizumab in Specific Type of...
2015-09-26Two Positive Studies of Genentech’s Investigational Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer Pr...
2015-09-08FDA Grants Genentech's Alectinib Priority Review for Specific Type of ALK-Positive Lung Cancer
2015-09-07Genentech to Present Data from 15 Medicines Across Its Portfolio of Cancer Immunotherapy and Targeted Medicines During t...
2015-09-03U.S. FDA Grants Breakthrough Therapy Designation for Genentech's Investigational Medicine ACE910 for People With Hemophi...
2015-08-16Pivotal Phase II Study Showed Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People with a Spec...
2015-08-12Pivotal Phase II Study of Investigational Medicine Venetoclax Met Primary Endpoint in a Hard-To-Treat Type of Chronic Ly...
2015-07-12In a Pivotal Study, Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type ...
2015-06-29Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®...
2015-06-10FDA Grants Breakthrough Therapy Designation for Actemra (tocilizumab) in Systemic Sclerosis
2015-05-31Genentech’s Perjeta Regimen Helped People with HER2-Positive Early Breast Cancer Live Longer without Their Disease Retur...
2015-05-30Genentech’s Gazyva® Extended the Time People with Refractory Indolent Non-Hodgkin’s Lymphoma Lived Without Their Disease...
2015-05-30Updated Data Showed Genentech’s Investigational Combination of Cobimetinib and Zelboraf (Vemurafenib) Helps People With ...
2015-05-13Genentech’s Investigational Immunotherapy MPDL3280A Doubled the Likelihood of Survival Compared with Chemotherapy in Peo...
2015-05-13Genentech’s Investigational Medicine Alectinib Shrank Tumors in Nearly Half of People with Specific Type of Lung Cancer
2015-05-13Genentech’s Investigational Immunotherapy MPDL3280A Reduced the Risk of Death by Half Compared with Chemotherapy in Peop...
2015-05-10Pivotal Data for Genentech Medicines in Lung and Blood Cancers To Be Presented at ASCO
2015-05-04Genentech Announces New STEM Education Initiative to Support South San Francisco Schools
2015-03-26Genentech Announces Plans To Expand Hillsboro Facility
2015-02-18FDA Grants Genentech's Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melano...
2015-02-06FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Treatment of Diabetic Retinopathy in People with Diabetic...
2015-02-03Genentech’s Phase III Study of Gazyva® Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
2015-02-01FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Cancer Immunotherapy MPDL3280A (anti-PDL1) i...
2014-12-24FDA Approves Gazyva® (Obinutuzumab) Supplemental Biologics License Application with New Data in Previously Untreated Chr...
2014-12-18Genentech Provides Update on Phase III MARIANNE Study in People with Previously Untreated Advanced HER2-Positive Breast ...
2014-12-14Genentech Submits New Drug Application to FDA for Investigational Cobimetinib Used in Combination with Zelboraf (vemuraf...
2014-12-05Genentech to Present Clinical Data from Six Different Medicines at American Society of Hematology (ASH) Annual Meeting
2014-11-14FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy to Treat Women with Platinum-Resistant Recurrent Ovaria...
2014-10-15FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States
2014-10-08FDA Grants Priority Review for Genentech’s Lucentis in Diabetic Retinopathy
2014-09-29Genentech’s Investigational Combination of Cobimetinib Plus Zelboraf (Vemurafenib) Provided Significant Benefit to Peopl...
2014-09-28Genentech’s Perjeta Regimen Extended the Lives of People With an Aggressive Type of Metastatic Breast Cancer By 15.7 Mon...
2014-08-14FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
2014-08-08Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic Retinopathy
2014-07-21FDA Grants Genentech’s Avastin Priority Review For Recurrent Platinum-resistant Ovarian Cancer
2014-07-14FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
2014-07-13Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf® (Vemurafenib), Helped People with A...
2014-07-01Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals
2014-05-31Investigational Immunotherapy Anti-PDL1 (MPDL3280A) Shrank Tumors in 43 Percent of People With a Specific Type of Metast...
2014-05-13Genentech to Present New Data on 27 Different Medicines at ASCO
2014-03-21FDA Approves Xolair® (omalizumab) for People with Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
2014-03-02Genentech Provides Update On Phase III Study Of Onartuzumab in People With Specific Type of Lung Cancer
2013-11-07Genentech’s Gazyva Helped People with One of the Most Common Forms of Blood Cancer Live Significantly Longer without The...
2013-11-01FDA Approves Gazyva™ (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
2013-10-21Genentech Gains FDA Approval for New Subcutaneous Formulation of Actemra® for use in Adult Patients Living with Moderate...
2013-10-13Genentech Announces Plans to Expand California Biologics Manufacturing Facilities
2013-10-10FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Chronic Idiopathic Urticari...
2013-09-30FDA Grants Genentech’s Perjeta Accelerated Approval for Use Before Surgery in People With HER2-Positive Early Stage Brea...
2013-09-27Genentech’s Kadcyla Helped People With Advanced HER2-Positive Breast Cancer Live Longer Without Their Disease Worsening ...
2013-09-12FDA Advisory Committee Recommends Accelerated Approval of Genentech’s Perjeta for Neoadjuvant Use in HER2-Positive Early...
2013-09-09Genentech Executive Vice President Wins Lasker Award
2013-07-23Genentech's Obinutuzumab (GA101) Delayed Disease Progression Longer Than Rituxan® in People with One of the Most Common ...
2013-07-02FDA Grants Genentech's Obinutuzumab (GA101) Priority Review for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
2013-07-01FDA Grants Genentech's Perjeta Regimen Priority Review for Use Before Surgery in HER2-Positive Early Stage Breast Cancer
2013-06-02Genentech's Medicine Avastin Plus Chemotherapy Improved Survival in Women with Advanced Cervical Cancer, Compared to Che...
2013-06-01Genentech Announces Final Phase III Study Results of Avastin Plus Radiotherapy and Chemotherapy in People with an Aggres...
2013-05-15Genentech's Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of th...
2013-05-14FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer
2013-05-14Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO
2013-04-30FDA Approves ACTEMRA® for Children Living with a Rare Form of Arthritis
2013-02-24Phase III Results Showed omalizumab Significantly Reduced Disease Severity in Patients with a Chronic form of Hives who ...
2013-02-22FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating Her2-Positi...
2013-01-30Obinutuzumab (GA101) Significantly Improved Progression-Free Survival in People With Chronic Lymphocytic Leukemia (CLL)
2013-01-23FDA Approves New Use of Avastin Plus Chemotherapy for People with Metastatic Colorectal Cancer
2012-12-21Genentech Announces FDA Approval of Tamiflu for the Treatment of Influenza in Infants
2012-12-07Genentech's Perjeta Significantly Extends Survival in People With HER2-Positive Metastatic Breast Cancer
2012-11-17Genentech Study Showed That Avastin Helped People with Newly Diagnosed Glioblastoma Live Longer without Their Disease Wo...
2012-11-10ADACTA Study Showed ACTEMRA Improved Signs and Symptoms of Rheumatoid Arthritis Significantly More Than Adalimumab as a ...
2012-11-06FDA Grants Genentech's Trastuzumab Emtansine (T-DM1) Priority Review for HER2-Positive Metastatic Breast Cancer
2012-10-12FDA Approves Expanded Indication for ACTEMRA® in Rheumatoid Arthritis
2012-10-01Genentech's Trastuzumab Emtansine (T-DM1) Significantly Extended Survival in People With Aggressive Form of Breast Cance...
2012-08-26New Data from Phase III EMILIA Study Showed Genentech's Trastuzumab Emtansine (T-DM1) Significantly Improved Survival of...
2012-08-10FDA Approves Lucentis® (Ranibizumab Injection) for Treatment of Diabetic Macular Edema (DME)
2012-08-09Genentech Study Showed That Adding Avastin to Radiation and Chemotherapy Significantly Extended the Time People with an ...
2012-07-26Genentech Reports Second Positive Study of ACTEMRA® Given by Subcutaneous Injection to Patients with Rheumatoid Arthriti...
2012-07-26FDA Advisory Committee Unanimously Recommends Approval of Lucentis for Treatment of Diabetic Macular Edema (DME)
2012-06-21New Data From Phase III Study Showed That People With HER2-Positive Metastatic Breast Cancer Lived Longer With Genentech...
2012-06-08FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer
2012-06-05Genentech's ACTEMRA® Improved Rheumatoid Arthritis Signs and Symptoms Significantly More Than Adalimumab as Single-Agent...
2012-06-02Genentech's Targeted Investigational Breast Cancer Medicine, Trastuzumab Emtansine (T-DM1), Reduced the Risk of Cancer W...
2012-06-02Genentech Data Showed That People With Metastatic Colorectal Cancer Lived Longer When They Continued on Avastin Plus Che...
2012-06-01Genentech Study Showed That Adding Avastin to Chemotherapy Cut the Risk of the Disease Getting Worse in Difficult-to-Tre...
2012-05-15Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
2012-05-02Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection
2012-03-29Genentech's Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer
2012-03-01Genentech's ACTEMRA® Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimuma...
2012-02-07FDA Grants Genentech's Pertuzumab Priority Review for Previously Untreated HER2-Positive Metastatic Breast Cancer
2012-01-30FDA Approves Erivedge (Vismodegib) Capsule, the First Medicine for Adults with Advanced Basal Cell Carcinoma
2012-01-13Genentech Announces First Milestone Payment to Device-Maker ForSight VISION4, Inc. in Development of Sustained Delivery ...
2011-12-07Genentech Announces Positive Results of Pivotal Phase III Study with Pertuzumab in HER2-Positive Metastatic Breast Cance...
2011-11-29Genentech to Present Important New Data for HER2-Positive Breast Cancer at 2011 San Antonio Breast Cancer Symposium
2011-11-18FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer
2011-11-08FDA Accepts Genentech's New Drug Application For Vismodegib in Advanced Form of Skin Cancer
2011-11-05Data Showed ACTEMRA Monotherapy Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
2011-10-19Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients f...
2011-09-24Genentech's Investigational Medicine T-DM1 Showed Improvement in Progression-Free Survival Compared to Standard of Care ...
2011-09-12Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer
2011-08-17FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Fo...
2011-07-14Pertuzumab Combined with Herceptin and Chemotherapy Significantly Extended the Time People with HER2-Positive Metastatic...
2011-06-29Genentech Provides Update from FDA Hearing on Avastin for Metastatic Breast Cancer
2011-06-28Two Pivotal Phase III Lucentis Studies Showed Patients With Diabetic Macular Edema Experienced Significant Improvements ...
2011-06-19Pivotal Study Showed Vismodegib Helped Shrink Tumors or Heal Lesions in People with Rare Form of Advanced Skin Cancer
2011-06-05Genentech Announces Vemurafenib Improved Survival in People With Metastatic Melanoma Who Have BRAF V600 Mutations
2011-06-04Genentech Announces Data to Show Avastin-Based Regimen Halved the Risk of Disease Getting Worse in Women with Recurrent ...
2011-06-02Tarceva Nearly Doubled the Time People with a Genetically Distinct Type of Lung Cancer Lived without Their Disease Getti...
2011-05-18MetMAb in Combination with Tarceva Doubled the Time People with Lung Cancer Lived without Their Disease Getting Worse
2011-05-17Genentech to Present Significant Progress in Advanced Skin, Lung and Ovarian Cancers at ASCO
2011-05-10New Drug Applications Submitted in the United States and Europe for Vemurafenib in Advanced Skin Cancer
2011-04-19FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
2011-04-15FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
2011-03-25Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema (DME)
2011-03-20Genentech Announces Positive Pivotal Phase II Results for Hedgehog Pathway Inhibitor in Advanced Basal Cell Carcinoma
2011-03-10Phase III Study of Lucentis Showed Rapid Vision Improvements Sustained for Two Years in Patients with Diabetic Macular E...
2011-02-24FDA Grants Genentech a Hearing on Avastin's Use for Metastatic Breast Cancer in the United States
2011-02-11Lucentis Phase III Study Meets Primary Endpoint For Improving Vision In Patients With Diabetic Macular Edema (DME)
2011-02-07Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
2011-01-28FDA Approves Rituxan for First-Line Maintenance Use in Follicular Lymphoma
2011-01-27Early Successful Readout of Tarceva Study in a Distinct Form of Lung Cancer
2011-01-18Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
2011-01-13Genentech Informs Customers of Important Information About Triad Group's Alcohol Prep Pads
2011-01-05FDA Grants Supplemental Approval for ACTEMRA® (tocilizumab)
2010-12-16Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
2010-12-10Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of W...
2010-12-05Phase II Study with First-in-Class Investigational Drug Demonstrates Improvement in Negative Symptoms in Patients with S...
2010-12-05Phase III Study Showed Rituxan® for Initial Use Followed by Continued Use Delayed the Need for Additional Therapy in Peo...
2010-11-07ACTEMRA Data Presented at ACR Annual Meeting on Rapid Response and Long-Term Efficacy in People with Rheumatoid Arthriti...
2010-11-04Genentech Reports Promising Phase II Results With New Targeted Approach in Advanced Melanoma
2010-10-20FDA Approves Herceptin For HER2-Positive Metastatic Stomach Cancer
2010-10-15Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
2010-09-17Genentech Provides Update on Avastin for Advanced Breast Cancer
2010-08-26Genentech Provides Update on FDA Application for T-DM1
2010-08-10FDA Approves Longer Use of Valcyte for Adult Kidney Transplant Patients at High Risk of Developing Cytomegalovirus (CMV)...
2010-07-20Genentech Provides Update From Avastin FDA Advisory Committee Meeting
2010-07-06Genentech Submits Application to FDA for Trastuzumab-DM1 in Previously Treated Advanced HER2-Positive Breast Cancer
2010-07-01Second Phase III Study Showed Avastin-Containing Regimen Helped Women with Ovarian Cancer Live Longer Without their Dise...
2010-06-22FDA Approves Lucentis® (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion
2010-06-06Phase III Study Showed Avastin-Based Regimen Helped Women with Advanced Ovarian Cancer Live Longer Without Their Disease...
2010-06-03Genentech's Scheller Wins Kavli Prize in Neuroscience
2010-05-20Phase III Study Showed First-Line Maintenance Use of Rituxan® Improved the Likelihood of People with Follicular Lymphoma...
2010-05-20Roche and Genentech to Present New Data on Different Approaches to Treating Cancer at ASCO
2010-04-22Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
2010-04-16FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
2010-03-16Genentech Submits Supplemental Biologics License Application for ACTEMRA (tocilizumab) for Prevention of Structural Join...
2010-03-11Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer
2010-02-24Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer
2010-02-22Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
2010-02-18FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
2010-01-15FDA Extends Review Period for Tarceva Application for First-line Maintenance Use in Advanced Non-small Cell Lung Cancer
2010-01-08FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
2009-12-16FDA Advisory Committee Recommends Against Approving Tarceva for First-Line Maintenance Use in Advanced Non-Small Cell Lu...
2009-12-12New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast Cancer
2009-12-11Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Women Previously Treated with Chemothera...
2009-12-10Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
2009-12-07Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
2009-11-18Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
2009-11-16Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with...
2009-10-17Genentech and Biogen Idec Receive a Complete Response from FDA for Earlier Use of Rituxan for Rheumatoid Arthritis
2009-10-17Phase III Study Showed Two Years of ACTEMRA ® (tocilizumab) Inhibited Progression of Joint Damage and Improved Disease R...
2009-10-04Two Phase III Studies of Lucentis Show Early and Sustained Improvement in Vision in Patients with Retinal Vein Occlusion
2009-09-16Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for...
2009-08-17Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Adva...
2009-08-02FDA Approves Avastin for the Most Common Type of Kidney Cancer
2009-07-30Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein Occlusion
2009-07-28Genentech Announces Appointment of Sandra J. Horning, M.D., to Senior Vice President, Global Head, Clinical Development ...
2009-07-19Xeloda®-Oxaliplatin Combination (Xelox) Shown to Be More Effective Than Standard Chemotherapy Regimen In Adjuvant Colon ...
2009-07-12New Data from Phase III Saturn Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemot...
2009-07-02Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
2009-05-30Phase III Study Showed Patients Lived Longer Without Advanced Lung Cancer Progressing When Tarceva Was Added to Avastin ...
2009-05-30Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer
2009-05-29Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer
2009-05-19Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
2009-05-14Genentech to Present Advances With Targeted Cancer Medicines at ASCO
2009-05-05FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
2009-04-21Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
2009-04-08Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market
2009-03-31FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Gliob...
2009-03-26Roche Completes Acquisition of Genentech
2009-03-18OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy...
2009-03-12Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innova...
2009-03-11Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
2009-03-06Genentech Urges Stockholders to Take No Action With Respect to Revised Offer From Roche
2009-02-24Genentech Receives Final Notification Upholding Cabilly Patent in Reexamination Proceeding
2009-02-23Genentech Announces March 2, 2009 Webcast of Investment Community Meeting
2009-02-23Genentech Special Committee Rejects Roche's $86.50 Offer as Inadequate
2009-02-19National Coalition for Cancer Survivorship, UCLA, Wellpoint, and Genentech Launch Initiative to Provide Coordinated Foll...
2009-02-09Genentech Urges Shareholders to Take No Action With Respect to Unsolicited Tender Offer from Roche
2009-02-02Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free S...
2009-01-30Special Committee of Genentech Board of Directors Responds to Roche's Announced Intention to Commence a Tender Offer
2009-01-21Genentech Announces Vice President Appointment in Research
2009-01-15Genentech Announces Full Year And Fourth Quarter 2008 Results
2008-12-22Genentech Announces January 15 Webcast of Financial and Other Business Results
2008-12-18Phase III Study Showed Rituxan Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis (RA...
2008-12-06Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
2008-11-23Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
2008-11-17Genentech Issues Dear Healthcare Provider Letter Regarding a 2nd Case of PML in a Raptiva Patient
2008-11-06Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advan...
2008-11-03Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Canc...
2008-10-27Rituxan Data in Patients With Rheumatoid Arthritis To Be Presented at The American College of Rheumatology Annual Scient...
2008-10-19Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
2008-10-14Genentech Announces Third Quarter 2008 Results
2008-10-06Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Rela...
2008-10-05Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin an...
2008-10-02Genentech, Glycart and Roche Enter Into Collaboration Agreement for Potential Cancer Therapy
2008-10-02Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient
2008-09-23Genentech Announces October 14 Webcast of Financial and Other Business Results
2008-09-10Genentech Announces Vice President Appointment In Research
2008-08-13Genentech Special Committee of Independent Directors Responds to Roche Proposal
2008-07-24Genentech Forms Special Committee of Independent Directors to Review Roche Proposal
2008-07-21Genentech Announces Receipt of Proposal From Roche
2008-07-14Genentech Announces Second Quarter 2008 Results
2008-06-23Genentech Announces July 14 Webcast of Financial and Other Business Results
2008-06-11Genentech Settles Dispute Related To Cabilly Patent
2008-05-31Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Women With Advanced HER2...
2008-05-19Genentech Announces June 2 Webcast Discussion of Data Presented at ASCO
2008-05-15Genentech Provides Update On Studies Of Investigational Biooncology Agents To Be Presented At The American Society Of Cl...
2008-05-15Genentech Provides Update on Avastin Program
2008-04-29Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythe...
2008-04-24Genentech Announces Decision In Contract Dispute
2008-04-20Genentech Provides Update on "AVAiL" Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous,...
2008-04-15Genentech Extends Stock Repurchase Program
1970-01-01Servier signs agreement with non-profit association La Chaîne de l'Espoir and announces creation of the Mécénat Servier ...
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.
E_CORE_WARNING Error in file Unknown at line 0: PHP Startup: Invalid library (appears to be a Zend Extension, try loading using zend_extension=opcache.so from php.ini)